Frontlight ResearchEarly access
SuspendedPhase 1/2
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
Key facts
- Who runs it
- Shanghai Minimally Invasive Surgery Center
- Where
- China1 site in 1 countryChoose a country to see its locations
- Trial code
- Status
- Suspended
- Phase
- Phase 1/2
- People taking part
- 100 people, planned
- Started
- 1 Jul 2022
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- camrelizumab+chemotherapy
- Chemotherapy
- Record updated
- 7 March 2024
- Why it stopped
- difficult in enrolling participants
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Subjects voluntarily join the study and sign an informed consent form, have good compliance and cooperate with follow-up
- Male or female patients between the ages of 18-75
- Patients diagnosed as gastric adenocarcinoma by histology or cytology
- Stage: Locally advanced stage (T3-4aN1-3M0)
- Have not received other immunotherapy drugs or chemotherapy drugs in the past
- ECOG (Eastern US Cooperative Oncology Group) score: 0-1 points
- Has sufficient organ and bone marrow function
Who cannot take part
- Those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, etc.)
- Received glucocorticosteroid or immunosuppressive therapy within 7 days before grouping
- Regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before grouping, patients with any bleeding or bleeding events NCI-CTC AE V5.0 grade ≥ 3, unhealed wounds, ulcers Or fracture
- Participated in other anti-tumor drug clinical trials within four weeks
- According to the judgment of the investigator, those with concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study
- Other malignant tumors that have appeared or are currently suffering from within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) ) And T1 (tumor infiltration basement membrane)]
- Accompanied by pleural effusion or ascites, causing respiratory syndrome (NCI-CTC AE V5.0 grade ≥ 2 dyspnea)
- Patients with any severe and/or uncontrollable disease;
- Patients with gastrointestinal diseases with bleeding tendency (such as active gastrointestinal ulcers) or patients determined by the researcher to cause gastrointestinal bleeding, perforation or obstruction
- Patients whose imaging shows that the tumor has invaded the tissues around important blood vessels or the investigator judges that the tumor is likely to invade important blood vessels and cause fatal bleeding during the follow-up study
- Those who have had arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism
- People with a history of psychotropic drug abuse and unable to quit or have mental disorders
- Known hypersensitivity to any study drug
- A distant metastasis occurs
- Female patients who are pregnant or breastfeeding
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
It is a single-center, open-lable, randomized controlled trial to prospectively investigate the effectiveness and safety of Camrelizumab combined with DOS regimen chemotherapy in neoadjuvant treatment of patients with locally advanced gastric cancer.
The 2 groups in the trial
- camrelizumab+chemotherapyTreatment being tested
neoadjuvant treatment with camrelizumab+chemotherapy
- chemotherapyExisting treatment, for comparison
neoadjuvant treatment with chemotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer: a Single-center, Open-label, Randomized Controlled Trial
- Record updated
- 7 March 2024